WebNov 1, 2024 · The MAIA study is, to our knowledge, the first randomised, phase 3 study that shows a significant improvement in overall survival with daratumumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients ineligible for transplantation with newly diagnosed multiple myeloma. WebJun 12, 2024 · The estimated percentage of patients alive without disease progression at 30 months was 70.6% (95% CI, 65.0%-75.4%) in the daratumumab arm, compared with 55.6% (95% CI, 49.5%-61.3%) in the control arm (HR, 0.56; 95% CI, 0.43-0.73; P < .001).
Daratumumab plus Lenalidomide and …
WebAug 11, 2024 · Given that overall costs are reduced and outcomes are improved when daratumumab is used as part of a first-line regimen, the economic analysis indicates that … WebSep 30, 2014 · Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival … how large is las vegas
Long-Term Follow-Up Shows Survival Benefit Maintained for Daratumumab ...
WebJul 1, 2024 · Dr. Thierry Facon (Lille University Hospital, Lille, France) discusses the results of the MAIA study which compared the overall survival results in transplant-ineligible … Web2 days ago · Abstract Number: CT050 / 8. Session Date: Monday, April 17, 2024, 9:00 am to 12:30 pm ET. Speaker/Lead Author: Mihail Obrocea, MD, MAIA’s Chief Medical Officer. Clinical trial abstract texts will be published online on AACR’s Online Itinerary Planner at 12:00 pm ET on April 14, 2024. WebFacon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2024;22 (11):1582-1596. Last Updated August 2024 cp-233680v1 FASPRO Local … how large is lithuania square miles